Category

NASDAQ

ViaSat-3 F2 Satellite Confirmed to Launch November 5, 2025 NASDAQ

ViaSat-3 F2 Satellite Confirmed to Launch November 5, 2025

Expected to more than double Viasats current network capacity, ViaSat-3 F2 is designed to fuel customer growth, supporting next-generation connectivity platforms such as Viasat Amara, NexusWave, and Government Hybrid SATCOM Architecture CARLSBAD, Calif. – WEBWIRE – Monday, November 3, 2025 Viasat, Inc.(NASDAQ: VSAT), a global leader in satellite communications, confirmed…
bubmag
November 3, 2025
SiriusXM Posts Solid Q3 2025 Financials — Including Net Income of Nearly $300 Million — As Pandora and Off-Platform Adverts Revenue Hits $416 Million NASDAQ

SiriusXM Posts Solid Q3 2025 Financials — Including Net Income of Nearly $300 Million — As Pandora and Off-Platform Adverts Revenue Hits $416 Million

Photo Credit: SiriusXM SiriusXM (NASDAQ: SIRI) has exceeded revenue expectations – and disclosed nearly $300 million in net income – for Q3 2025, when Pandora and off-platform advertising generated a cool $416 million. The overarching SiriusXM just recently posted its earnings for July, August, and September, pointing to $2.16 billion…
bubmag
October 31, 2025
Agilysys Wins 2025 HTNG TechOvation Award for Agilysys Book with S.P.E.N.D. Technology NASDAQ

Agilysys Wins 2025 HTNG TechOvation Award for Agilysys Book with S.P.E.N.D. Technology

(L to R) Rosanna Maietta, President & CEO of AHLA, Frank Pitsikalis, Senior Vice President, and David Sjolander, VP, HTNG Operations of AHLA — Photo by Agilysys Agilysys, Inc. (Nasdaq: AGYS), a leading global provider of next-generation hospitality software and services, today announced that its Book with S.P.E.N.D. (Stay Package…
bubmag
October 31, 2025
Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders NASDAQ

Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders

HONG KONG, Oct 30, 2025 - (ACN Newswire) – Everest Medicines (HKEX:1952.HK) today announced that it has acquired an exclusive license with Visara, Inc. (“Visara”), a subsidiary of NovaBridge Biosciences (formally known as I-Mab, and is a company listed on the Nasdaq Global Market trading under the symbol “NBP”), to…
bubmag
October 30, 2025